View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2015	May 05, 2015
Document and Entity Information
Entity Registrant Name	Sunshine Heart, Inc.
Entity Central Index Key	0001506492
Document Type	10-Q
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,297,177
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 37,027	$ 31,293
Accounts receivable	59	59
Other current assets	921	360
Total current assets	38,007	31,712
Property, plant and equipment, net	653	661
Other assets	135
TOTAL ASSETS	38,795	32,373
Current liabilities
Current portion of long-term debt	705
Accounts payable	2,233	2,079
Accrued salaries, wages, and other compensation	741	1,079
Total current liabilities	3,679	3,158
Long-term debt, net of discount	5,043
Total liabilities	8,722	3,158
Commitments and contingencies
Stockholders' equity
Common stock as of March 31, 2015 and December 31, 2014, par value $0.0001 per share; authorized 100,000,000 shares: issued and outstanding 18,233,185 and 16,982,642, respectively	2	2
Additional paid-in capital	162,451	154,540
Accumulated other comprehensive income:
Foreign currency translation adjustment	1,282	1,272
Accumulated deficit	(133,662)	(126,599)
Total stockholders' equity	30,073	29,215
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	38,795	32,373
Series A junior participating preferred stock
Stockholders' equity
Preferred stock
Preferred stock
Stockholders' equity
Preferred stock

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	18,233,185	16,982,642
Common stock, shares outstanding	18,233,185	16,982,642
Series A junior participating preferred stock
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	30,000	30,000
Preferred Stock, Shares outstanding	0	0
Preferred stock
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	39,970,000	39,970,000
Preferred Stock, Shares outstanding	0	0

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Consolidated Statements of Operations and Comprehensive Loss
Net sales	$ 59	$ 59
Operating expenses:
Selling, general and administrative	2,186	2,361
Research and development	4,865	4,063
Total operating expenses	7,051	6,424
Loss from operations	(6,992)	(6,365)
Other income (expense), net	(66)	33
Loss before income taxes	(7,058)	(6,332)
Income tax expense	5
Net loss	$ (7,063)	$ (6,332)
Basic and diluted loss per share (in dollars per share)	$ (0.40)	$ (0.38)
Weighted average shares outstanding - basic and diluted (in shares)	17,509	16,859
Other comprehensive income:
Foreign currency translation adjustments	$ 10	$ (19)
Total comprehensive loss	$ (7,053)	$ (6,351)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Consolidated Statements of Cash Flows
Net loss	$ (7,063)	$ (6,332)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation	80	61
Stock-based compensation expense, net	743	632
Amortization of debt discount	14
Changes in operating assets and liabilities
Other current assets	(561)	(468)
Other assets	(135)
Accounts payable and accrued expenses	(162)	(580)
Net cash used in operations	(7,084)	(6,687)
Investing activities:
Purchase of property and equipment	(72)	(46)
Net cash used in investing activities	(72)	(46)
Financing activities:
Net proceeds from the sale of common stock	6,902	16
Proceeds from borrowings on long-term debt	6,000
Net cash provided by financing activities	12,902	16
Effect of exchange rate changes on cash	(12)	2
Net increase (decrease) in cash and cash equivalents	5,734	(6,715)
Cash and cash equivalents-beginning of period	31,293	54,136
Cash and cash equivalents-end of period	37,027	47,421
Supplement schedule of non-cash activities
Stock options and restricted stock units classified as liabilities, net		$ (278)
Warrants issued in connection with debt financing	$ 266

Nature of Business and Significant Accounting Policies	3 Months Ended
Nature of Business and Significant Accounting Policies	Mar. 31, 2015
Nature of Business and Significant Accounting Policies
Nature of Business and Significant Accounting Policies	Note 1 - Basis of Presentation Unless otherwise specified or indicated by the context, “Sunshine Heart,” “Company,” “we,” “us” and “our” refer to Sunshine Heart, Inc. and its subsidiaries. Principles of Consolidation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Sunshine Heart, Inc. and its subsidiaries for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2014 and 2013 and through March 31, 2015, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2014, the Company had an accumulated deficit of $126.6 million and it expects to incur losses for the foreseeable future. To date, the Company has been funded by debt and equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. The Company’s ability to continue as a going concern is dependent on the Company’s ability to raise additional capital based on the achievement of existing milestones as and when required. Should future capital raising be unsuccessful, the Company may not be able to continue as a going concern. Furthermore, the ability of the Company to continue as a going concern is subject to the ability of the Company to develop and successfully commercialize the product being developed. If the Company is unable to obtain such funding of an amount and timing necessary to meet its future operational plans, or to successfully commercialize its intellectual property, the Company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern. Earnings per share: Basic earnings per share is computed based on the weighted average number of common shares outstanding. Diluted earnings per share is computed based on the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include warrants, stock options and other stock-based awards granted under stock-based compensation plans. These potentially dilutive shares totaling 2,931,306 and 3,512,005 for the three months ended March 31, 2015 and 2014, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company’s net loss in each of those periods. New Accounting Pronouncements: In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The standard allows the Company to transition to the new model using either a full or modified retrospective approach, and early adoption is not permitted. The Company is currently evaluating the impact that this standard will have on its business practices, financial condition, results of operations and disclosures. In August 2014, the FASB amended guidance relating to the presentation and disclosure of the uncertainties of an entity’s ability to continue as a going concern. This guidance explicitly requires management of a company to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosure in certain circumstances. This guidance is effective for the Company’s interim and annual reporting periods beginning January 1, 2017, with early adoption permitted. The Company is evaluating the impact that the adoption of this standard will have, if any, on its financial statements and disclosures.

Debt	3 Months Ended
Debt	Mar. 31, 2015
Debt Disclosure
Debt	Note 2 - Debt On February 18, 2015, the Company entered into a loan and security agreement with Silicon Valley Bank for proceeds of up to $10.0 million at an annual interest rate of 7.0%. Under this agreement, the Company received $6.0 million at closing and has available an additional $2.0 million after the notification that the FDA had accepted its statistical interim analysis plan. The remaining $2.0 million will become available upon the Company enrolling its one hundredth patient in the COUNTER HF trial on or before September 30, 2015. Total borrowings under this facility totaled $6.0 million as of March 31, 2015. The proceeds from the loan will be used for general corporate and working capital purposes. The Company is entitled to make interest only payments until January 1, 2016. Commencing on January 1, 2016, and continuing on the first day of each calendar month thereafter, the Company is required to repay the advances made in twenty-four consecutive equal monthly installments. The agreement is secured by a security interest in assets of the Company and its current and future subsidiaries, including a security interest in intellectual property proceeds, but excluding a current security interest in intellectual property. The agreement contains customary representations (tested on a continual basis) and covenants that, subject to exceptions, restrict the Company’s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are not related to its existing business. Upon repayment of the term loans, the Company is also required to make a final payment to the Lender equal to 5% of the original principal amount of the term loans. In connection with the loan and security agreement, the Company issued 68,996 warrants at an exercise price of $5.22 per share to Silicon Valley Bank and one of its affiliates. The warrants have a life of ten years and were fully vested at the date of grant. The Company valued these warrants at $3.86 per share utilizing the Black Scholes valuation model utilizing the following assumptions: expected dividend yield of 0%, an expected stock price volatility of 88.07%, a risk-free interest rate of 1.86% and expected option lives of 6.25 years. The value of these warrants was recorded as debt discount in the accompanying balance sheet and will be amortized to interest expense over the term of the debt agreement using the effective interest rate method. As of March 31, 2015, $252,000 of unamortized debt discount was netted against long-term debt.

Equity	3 Months Ended
Equity	Mar. 31, 2015
Equity
Equity	Note 3 - Equity ATM Sales: In March 2014, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company LLC (“Cowen”) to sell from time to time, in “at the market” offerings, shares of its common stock having an aggregate offering price of up to $40.0 million. During the three months ended March 31, 2015, the Company sold 1,214,395 shares of common stock for net proceeds of $6.9 million after stock issuance costs of $0.2 million. There were no issuances of common stock under this facility in the three months ended March 31, 2014. As of March 31, 2015, the Company had a total of $32.8 million available for future sales under the Sales Agreement.

Stock-Based Compensation

3 Months Ended

Mar. 31, 2015

Stock-Based Compensation

Stock-Based Compensation

Note 4 - Stock-Based Compensation

Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation, the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period.

The following table presents the classification of stock-based compensation expense recognized for the three months ended March 31, 2015 and 2014:

	Three months ended March 31,
(in thousands)	2015		2014
Selling, general and administrative expense	$	567	$	468
Research and development expense	300		267
Total stock-based compensation expense	$	867	$	735

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2015

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Note 5 - Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities. The Company believes that the carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities.

Pursuant to the requirements of Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (the “ASC”) Topic 820 “Fair Value Measurement,” the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges.

Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

All cash equivalents are considered Level 1 measurements for all periods presented. The Company does not have any financial instruments classified as Level 2 or Level 3 and there were no movements between these categories during the periods ended March 31, 2015 and December 31, 2014.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2015
Income Taxes
Income Taxes	Note 6 — Income Taxes The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying financial statements. As of March 31, 2015, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties in its Annual Report on Form 10-K for the year ended December 31, 2014.

Nature of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Nature of Business and Significant Accounting Policies
Principles of Consolidation	Principles of Consolidation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Sunshine Heart, Inc. and its subsidiaries for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
Going Concern	Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2014 and 2013 and through March 31, 2015, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2014, the Company had an accumulated deficit of $126.6 million and it expects to incur losses for the foreseeable future. To date, the Company has been funded by debt and equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. The Company’s ability to continue as a going concern is dependent on the Company’s ability to raise additional capital based on the achievement of existing milestones as and when required. Should future capital raising be unsuccessful, the Company may not be able to continue as a going concern. Furthermore, the ability of the Company to continue as a going concern is subject to the ability of the Company to develop and successfully commercialize the product being developed. If the Company is unable to obtain such funding of an amount and timing necessary to meet its future operational plans, or to successfully commercialize its intellectual property, the Company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.
Earnings Per Share	Earnings per share: Basic earnings per share is computed based on the weighted average number of common shares outstanding. Diluted earnings per share is computed based on the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include warrants, stock options and other stock-based awards granted under stock-based compensation plans. These potentially dilutive shares totaling 2,931,306 and 3,512,005 for the three months ended March 31, 2015 and 2014, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company’s net loss in each of those periods.
Recent Accounting Pronouncements	New Accounting Pronouncements: In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The standard allows the Company to transition to the new model using either a full or modified retrospective approach, and early adoption is not permitted. The Company is currently evaluating the impact that this standard will have on its business practices, financial condition, results of operations and disclosures. In August 2014, the FASB amended guidance relating to the presentation and disclosure of the uncertainties of an entity’s ability to continue as a going concern. This guidance explicitly requires management of a company to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosure in certain circumstances. This guidance is effective for the Company’s interim and annual reporting periods beginning January 1, 2017, with early adoption permitted. The Company is evaluating the impact that the adoption of this standard will have, if any, on its financial statements and disclosures.

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2015

Stock-Based Compensation

Summary of stock-based compensation expense

	Three months ended March 31,
(in thousands)	2015		2014
Selling, general and administrative expense	$	567	$	468
Research and development expense	300		267
Total stock-based compensation expense	$	867	$	735

Nature of Business and Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Going Concern
Accumulated deficit	$ 133,662		$ 126,599
Antidilutive securities
Shares reserved for outstanding stock warrants and options and restricted stock units excluded from the computation of loss per share due to their antidilutive effect	2,931,306	3,512,005

Debt (Details)		3 Months Ended
Debt (Details)	Feb. 18, 2015 USD ($) item $ / shares shares	Mar. 31, 2015 USD ($)
Debt Disclosure
Payment percentage of principal amount		5
Loan and Security Agreement with Silicon Valley Bank
Debt Disclosure
Proceeds from loan		$ 6,000,000
Fixed interest rate	7.00%
Proceeds received at closing	$ 6,000,000
Proceeds to be received upon the company's announcement that the FDA had accepted its statistical interim analysis plan	2,000,000
Proceeds to be received upon the company enrolling its 100th patient in the COUNTER HF study	$ 2,000,000
Number of consecutive equal monthly installments of principal and interest repayment \| item	24
Loan and Security Agreement with Silicon Valley Bank \| Warrants
Debt Disclosure
Warrants issued \| shares	68,996
Exercise price of warrants (in dollars per share) \| $ / shares	$ 5.22
Term of warrants	10 years
Share Price \| $ / shares	$ 3.86
Expected dividend rate	0.00%
Expected volatility rate	88.07%
Risk-free interest rate	1.86%
Expected option life	6 years 3 months
Unamortized debt discount		$ 252,000
Maximum \| Loan and Security Agreement with Silicon Valley Bank
Debt Disclosure
Proceeds from loan	$ 10,000,000

Equity (Details) - USD ($) $ in Thousands		3 Months Ended
Equity (Details) - USD ($) $ in Thousands	Mar. 21, 2014	Mar. 31, 2015	Mar. 31, 2014
Sales of common stocks
Proceeds, net of transaction costs		$ 6,902	$ 16
Cowen
Sales of common stocks
Common stock sold (in shares)		1,214,395	0
Proceeds, net of transaction costs		$ 6,900
Aggregate offering price of shares of common stock	$ 40,000
Stock issuance cost		200
Value of common stock available for future sale		$ 32,800

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014
Stock-based compensation
Compensation expense	$ 867	$ 735
Selling, general and administrative expense.
Stock-based compensation
Compensation expense	567	468
Research and development expense.
Stock-based compensation
Compensation expense	$ 300	$ 267